Bank Of Montreal

Direxion Daily Small Cap Bull 3X ETF

SPDR S&P Retail ETF

ProShares UltraPro Dow30

ProShares UltraShort Bloomberg Natrl Gas

Guggenheim Solar ETF

Direxion Technology Bear 3X Shares

Materials Select Sector SPDR

ProShares Trust ProShares Short Bitcoin Strategy ETF

ProShares Bitcoin Strategy ETF

Direxion Daily Small Cap Bear 3X ETF

ProShares Ultra Bloomberg Natural Gas

Direxion Daily Technology Bull 3X ETF

ARK Innovation ETF

Direxion Dly S&P Oil&Gs Ex&Prd Br 3X ETF

Magal Security Systems Ltd.

Direxion Financial Bear 3X Shar

Direxion Daily Semicondct Bull 3X ETF

JELD-WEN Holding Inc. Common Stock

Las Vegas Sands Corp. Common Stock

Century Communities Inc. Common Stock

Kontoor Brands Inc. Common Stock

Bath & Body Works Inc.

RLJ Lodging Trust Common Shares of Beneficial Interest $0.01 par value

Leggett & Platt Incorporated Common Stock

Snap Inc. Class A Common Stock

Cleveland-Cliffs Inc. Common Stock

Civitas Resources Inc. Common Stock

Archer Aviation Inc. Class A Common Stock

AMC Entertainment Holdings Inc. Class A Common Stock

Oklo Inc.

QuantumScape Corporation Class A Common Stock

Sea Limited American Depositary Shares each representing one Class A Ordinary Share

Cameco Corporation Common Stock

Twilio Inc. Class A Common Stock

Spotify Technology S.A. Ordinary Shares

Cloudflare Inc. Class A Common Stock

Molina Healthcare Inc Common Stock

Click here to get full coverage on PGEN’s Unexpected 9% Surge: What’s Behind It? - StocksToTrade

PGEN’s Unexpected 9% Surge: What’s Behind It?  StocksToTrade

PGEN’s Unexpected 9% Surge: What’s Behind It? - StocksToTrade

Click here to get full coverage on FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025 - PR Newswire

FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025  PR Newswire

FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025 - PR Newswire

Click here to get full coverage on Notable Wednesday Option Activity: TTEC, UAL, PGEN - Nasdaq

Notable Wednesday Option Activity: TTEC, UAL, PGEN  Nasdaq

Notable Wednesday Option Activity: TTEC, UAL, PGEN - Nasdaq

Click here to get full coverage on Why Precigen, Inc. (PGEN) is Skyrocketing So Far in 2025 - Yahoo Finance

Why Precigen, Inc. (PGEN) is Skyrocketing So Far in 2025  Yahoo Finance

Why Precigen, Inc. (PGEN) is Skyrocketing So Far in 2025 - Yahoo Finance

Click here to get full coverage on Precigen's Breakthrough RRP Treatment Achieves 51% Complete Response, FDA Decision by August - Stock Titan

Precigen's Breakthrough RRP Treatment Achieves 51% Complete Response, FDA Decision by August  Stock Titan

Precigen's Breakthrough RRP Treatment Achieves 51% Complete Response, FDA Decision by August - Stock Titan

Click here to get full coverage on Precigen: Successful Proof Of Platform, But Cash Worries Remain (NASDAQ:PGEN) - Seeking Alpha

Precigen: Successful Proof Of Platform, But Cash Worries Remain (NASDAQ:PGEN)  Seeking Alpha

Precigen: Successful Proof Of Platform, But Cash Worries Remain (NASDAQ:PGEN) - Seeking Alpha

Click here to get full coverage on TVA Documents Reveal New Details About How America’s Major Utilities Fight Clean Air Regulations - Energy and Policy Institute

TVA Documents Reveal New Details About How America’s Major Utilities Fight Clean Air Regulations  Energy and Policy Institute

TVA Documents Reveal New Details About How America’s Major Utilities Fight Clean Air Regulations - Energy and Policy Institute

Click here to get full coverage on PGEN Stock Soars to 52-Week High, Reaching $1.93 Amid Growth - Investing.com

PGEN Stock Soars to 52-Week High, Reaching $1.93 Amid Growth  Investing.com

PGEN Stock Soars to 52-Week High, Reaching $1.93 Amid Growth - Investing.com

Click here to get full coverage on Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock - PR Newswire

Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock  PR Newswire

Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock - PR Newswire

Click here to get full coverage on PGEN Stock Surges More Than 40% in a Week: What's Driving the Rally? - Yahoo Finance

PGEN Stock Surges More Than 40% in a Week: What's Driving the Rally?  Yahoo Finance

PGEN Stock Surges More Than 40% in a Week: What's Driving the Rally? - Yahoo Finance

Click here to get full coverage on Breakthrough RRP Treatment PRGN-2012 Nears FDA Decision with 51% Complete Response Rate - Stock Titan

Breakthrough RRP Treatment PRGN-2012 Nears FDA Decision with 51% Complete Response Rate  Stock Titan

Breakthrough RRP Treatment PRGN-2012 Nears FDA Decision with 51% Complete Response Rate - Stock Titan

Click here to get full coverage on Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis - PR Newswire

Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis  PR Newswire

Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis - PR Newswire

Click here to get full coverage on Is Precigen (PGEN) The Hot Biotech Stock Under $5? - Yahoo Finance

Is Precigen (PGEN) The Hot Biotech Stock Under $5?  Yahoo Finance

Is Precigen (PGEN) The Hot Biotech Stock Under $5? - Yahoo Finance

Click here to get full coverage on Major Rare Disease Summit: Precigen Tackles RRP Crisis Affecting 125,000 Patients - Stock Titan

Major Rare Disease Summit: Precigen Tackles RRP Crisis Affecting 125,000 Patients  Stock Titan

Major Rare Disease Summit: Precigen Tackles RRP Crisis Affecting 125,000 Patients - Stock Titan

Click here to get full coverage on Precigen Reports Third Quarter 2024 Financial Results and Business Updates - PR Newswire

Precigen Reports Third Quarter 2024 Financial Results and Business Updates  PR Newswire

Precigen Reports Third Quarter 2024 Financial Results and Business Updates - PR Newswire

Click here to get full coverage on Precigen, Inc. (PGEN) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance

Precigen, Inc. (PGEN) Reports Q4 Loss, Lags Revenue Estimates  Yahoo Finance

Precigen, Inc. (PGEN) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance

Click here to get full coverage on Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference - PR Newswire

Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference  PR Newswire

Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference - PR Newswire

Click here to get full coverage on Precigen Inc (PGEN) Q4 2024 Earnings Call Highlights: Navigating Challenges and Seizing ... - Yahoo Finance

Precigen Inc (PGEN) Q4 2024 Earnings Call Highlights: Navigating Challenges and Seizing ...  Yahoo Finance

Precigen Inc (PGEN) Q4 2024 Earnings Call Highlights: Navigating Challenges and Seizing ... - Yahoo Finance

Click here to get full coverage on Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock - PR Newswire

Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock  PR Newswire

Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock - PR Newswire

Click here to get full coverage on Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch - PR Newswire

Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch  PR Newswire

Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch - PR Newswire

Click here to get full coverage on Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement (PGEN) - Seeking Alpha

Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement (PGEN)  Seeking Alpha

Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement (PGEN) - Seeking Alpha

Click here to get full coverage on JMP Securities Reiterates PGEN with Market Outperform Rating | P - GuruFocus

JMP Securities Reiterates PGEN with Market Outperform Rating | P  GuruFocus

JMP Securities Reiterates PGEN with Market Outperform Rating | P - GuruFocus

Click here to get full coverage on Precigen stock price target maintained at $6 by JMP on RRP therapy - Investing.com

Precigen stock price target maintained at $6 by JMP on RRP therapy  Investing.com

Precigen stock price target maintained at $6 by JMP on RRP therapy - Investing.com

Click here to get full coverage on Editorial Note: MiR172-APETALA2-like genes integrate vernalization and plant age to control flowering time in wheat - PLOS

Editorial Note: MiR172-APETALA2-like genes integrate vernalization and plant age to control flowering time in wheat  PLOS

Editorial Note: MiR172-APETALA2-like genes integrate vernalization and plant age to control flowering time in wheat - PLOS

Click here to get full coverage on Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch - PR Newswire

Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch  PR Newswire

Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch - PR Newswire

Click here to get full coverage on Precigen First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

Precigen First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags  Yahoo Finance

Precigen First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

Click here to get full coverage on Precigen Reports First Quarter 2025 Financial Results and Business Updates - Yahoo Finance

Precigen Reports First Quarter 2025 Financial Results and Business Updates  Yahoo Finance

Precigen Reports First Quarter 2025 Financial Results and Business Updates - Yahoo Finance

Click here to get full coverage on Stifel maintains Precigen stock Buy rating, $7 target post-FDA update - Investing.com

Stifel maintains Precigen stock Buy rating, $7 target post-FDA update  Investing.com

Stifel maintains Precigen stock Buy rating, $7 target post-FDA update - Investing.com

Click here to get full coverage on Precigen earnings missed by $0.10, revenue topped estimates - Investing.com

Precigen earnings missed by $0.10, revenue topped estimates  Investing.com

Precigen earnings missed by $0.10, revenue topped estimates - Investing.com

Click here to get full coverage on Precigen Completes Series Of Transactions To Solidify Healthcare Focus - PR Newswire

Precigen Completes Series Of Transactions To Solidify Healthcare Focus  PR Newswire

Precigen Completes Series Of Transactions To Solidify Healthcare Focus - PR Newswire

Click here to get full coverage on Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse™ Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated Cancers - PR Newswire

Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse™ Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated Cancers  PR Newswire

Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse™ Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metastatic HPV-associated Cancers - PR Newswire

Click here to get full coverage on Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting - PR Newswire

Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting  PR Newswire

Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting - PR Newswire

Click here to get full coverage on PGEN Stock Price and Chart — NASDAQ:PGEN - TradingView

PGEN Stock Price and Chart — NASDAQ:PGEN  TradingView

PGEN Stock Price and Chart — NASDAQ:PGEN - TradingView

Click here to get full coverage on News Releases - PBBM: New PNP Chief Torre to lead with precision, compassion, accountability - Presidential Communications Office

News Releases - PBBM: New PNP Chief Torre to lead with precision, compassion, accountability  Presidential Communications Office

News Releases - PBBM: New PNP Chief Torre to lead with precision, compassion, accountability - Presidential Communications Office

Click here to get full coverage on The social genome: Current findings and implications for the study of human genetics - PLOS

The social genome: Current findings and implications for the study of human genetics  PLOS

The social genome: Current findings and implications for the study of human genetics - PLOS

Click here to get full coverage on Correction: The Role of the Mammalian DNA End-processing Enzyme Polynucleotide Kinase 3’-Phosphatase in Spinocerebellar Ataxia Type 3 Pathogenesis - PLOS

Correction: The Role of the Mammalian DNA End-processing Enzyme Polynucleotide Kinase 3’-Phosphatase in Spinocerebellar Ataxia Type 3 Pathogenesis  PLOS

Correction: The Role of the Mammalian DNA End-processing Enzyme Polynucleotide Kinase 3’-Phosphatase in Spinocerebellar Ataxia Type 3 Pathogenesis - PLOS

Click here to get full coverage on Shuffling effector genes through mini-chromosomes - PLOS

Shuffling effector genes through mini-chromosomes  PLOS

Shuffling effector genes through mini-chromosomes - PLOS

Click here to get full coverage on Expression of Concern: NKILA represses nasopharyngeal carcinoma carcinogenesis and metastasis by NF-κB pathway inhibition - PLOS

Expression of Concern: NKILA represses nasopharyngeal carcinoma carcinogenesis and metastasis by NF-κB pathway inhibition  PLOS

Expression of Concern: NKILA represses nasopharyngeal carcinoma carcinogenesis and metastasis by NF-κB pathway inhibition - PLOS

Click here to get full coverage on Correction: Regulation of ATG4B Stability by RNF5 Limits Basal Levels of Autophagy and Influences Susceptibility to Bacterial Infection - PLOS

Correction: Regulation of ATG4B Stability by RNF5 Limits Basal Levels of Autophagy and Influences Susceptibility to Bacterial Infection  PLOS

Correction: Regulation of ATG4B Stability by RNF5 Limits Basal Levels of Autophagy and Influences Susceptibility to Bacterial Infection - PLOS

Click here to get full coverage on Precigen Enters into Agreement to Divest Non-Healthcare Subsidiary Trans Ova Genetics - PR Newswire

Precigen Enters into Agreement to Divest Non-Healthcare Subsidiary Trans Ova Genetics  PR Newswire

Precigen Enters into Agreement to Divest Non-Healthcare Subsidiary Trans Ova Genetics - PR Newswire

Click here to get full coverage on Kingdom Come - PLOS

Kingdom Come - PLOS

Click here to get full coverage on Genes influence facial attractiveness through intricate biological relationships - PLOS

Genes influence facial attractiveness through intricate biological relationships  PLOS

Genes influence facial attractiveness through intricate biological relationships - PLOS

Click here to get full coverage on By what name shall I call thee? - PLOS

By what name shall I call thee? - PLOS

Click here to get full coverage on Breaking the Y - PLOS

Breaking the Y - PLOS

Click here to get full coverage on Predicting longevity responses to dietary restriction: A stepping stone toward precision geroscience - PLOS

Predicting longevity responses to dietary restriction: A stepping stone toward precision geroscience  PLOS

Predicting longevity responses to dietary restriction: A stepping stone toward precision geroscience - PLOS

Click here to get full coverage on C. elegans germline cell death, live! - PLOS

C. elegans germline cell death, live!  PLOS

C. elegans germline cell death, live! - PLOS

Click here to get full coverage on Endless microbes most beautiful and most wonderful - PLOS

Endless microbes most beautiful and most wonderful  PLOS

Endless microbes most beautiful and most wonderful - PLOS

Click here to get full coverage on Fish mutant, where is thy phenotype? - PLOS

Fish mutant, where is thy phenotype?  PLOS

Fish mutant, where is thy phenotype? - PLOS

Click here to get full coverage on ABCs of Insect Resistance to Bt - PLOS

ABCs of Insect Resistance to Bt - PLOS

Click here to get full coverage on Expanding human variation at PLOS Genetics - PLOS

Expanding human variation at PLOS Genetics  PLOS

Expanding human variation at PLOS Genetics - PLOS

Click here to get full coverage on Up For A Challenge (U4C): Stimulating innovation in breast cancer genetic epidemiology - PLOS

Up For A Challenge (U4C): Stimulating innovation in breast cancer genetic epidemiology  PLOS

Up For A Challenge (U4C): Stimulating innovation in breast cancer genetic epidemiology - PLOS

Click here to get full coverage on Combating the Sigatoka Disease Complex on Banana - PLOS

Combating the Sigatoka Disease Complex on Banana  PLOS

Combating the Sigatoka Disease Complex on Banana - PLOS

Click here to get full coverage on CPNP MARBIL: ‘REVITALIZED KATOK’ SAFEGUARDS COMMUNITIES BY ENFORCING RESPONSIBLE GUN OWNERSHIP, NOT POLITICAL INTIMIDATION Philippine National Police (PNP) Chief, Police General Rommel Francisco D. Marbil, reassured the - Facebook

CPNP MARBIL: ‘REVITALIZED KATOK’ SAFEGUARDS COMMUNITIES BY ENFORCING RESPONSIBLE GUN OWNERSHIP, NOT POLITICAL INTIMIDATION Philippine National Police (PNP) Chief, Police General Rommel Francisco D. Marbil, reassured the  Facebook

CPNP MARBIL: ‘REVITALIZED KATOK’ SAFEGUARDS COMMUNITIES BY ENFORCING RESPONSIBLE GUN OWNERSHIP, NOT POLITICAL INTIMIDATION Philippine National Police (PNP) Chief, Police General Rommel Francisco D. Marbil, reassured the - Facebook

Click here to get full coverage on Correction: Suppression of class I compensated cell enlargement by xs2 mutation is mediated by salicylic acid signaling - PLOS

Correction: Suppression of class I compensated cell enlargement by xs2 mutation is mediated by salicylic acid signaling  PLOS

Correction: Suppression of class I compensated cell enlargement by xs2 mutation is mediated by salicylic acid signaling - PLOS

Click here to get full coverage on PNP PROMOTES 33,143 PERSONNEL IN NATIONWIDE OATH-TAKING CEREMONY The Philippine National Police (PNP) held a simultaneous oath-taking, pinning, and donning of ranks for newly promoted 2nd Level Uniformed Personnel today at the PNP - Facebook

PNP PROMOTES 33,143 PERSONNEL IN NATIONWIDE OATH-TAKING CEREMONY The Philippine National Police (PNP) held a simultaneous oath-taking, pinning, and donning of ranks for newly promoted 2nd Level Uniformed Personnel today at the PNP  Facebook

PNP PROMOTES 33,143 PERSONNEL IN NATIONWIDE OATH-TAKING CEREMONY The Philippine National Police (PNP) held a simultaneous oath-taking, pinning, and donning of ranks for newly promoted 2nd Level Uniformed Personnel today at the PNP - Facebook

Click here to get full coverage on PNP Chief Leads Turnover and Blessing of Newly Constructed Home for Typhoon-Affected Police Personnel in Batangas In a remarkable demonstration of unity and compassion, Philippine National Police (PNP) Chief, PGEN Rommel Francisco D. Marbil, spe - Facebook

PNP Chief Leads Turnover and Blessing of Newly Constructed Home for Typhoon-Affected Police Personnel in Batangas In a remarkable demonstration of unity and compassion, Philippine National Police (PNP) Chief, PGEN Rommel Francisco D. Marbil, spe  Facebook

PNP Chief Leads Turnover and Blessing of Newly Constructed Home for Typhoon-Affected Police Personnel in Batangas In a remarkable demonstration of unity and compassion, Philippine National Police (PNP) Chief, PGEN Rommel Francisco D. Marbil, spe - Facebook

Precigen Inc (PGEN)

Price Chart

Key Statistics

Technicals

About PGEN

Latest News

PGEN’s Unexpected 9% Surge: What’s Behind It? - StocksToTrade

FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025 - PR Newswire

Notable Wednesday Option Activity: TTEC, UAL, PGEN - Nasdaq

Advanced Charts

Top Gainers

Top Losers